(MedPage Today) -- An FDA advisory committee on Monday unanimously supported the investigational drug donanemab for treating early Alzheimer's disease.
An advisory committee to the Food and Drug Administration found the drug was safe and effective at slowing the progression of the disease, setting the stage for the agency to approve it.
(AP) — A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia caused by the brain-robbing disease. Food…
The man accused of beating up Jeffrey Epstein in a federal jail has been sentenced for masterminding a quadruple murder that killed a man and 3 witnesses.
Eli Lilly’s experimental Alzheimer’s drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Administration.
A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia caused by the brain-robbing disease.
WASHINGTON — A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia caused by the brain-robbing disease.